Trial Profile
A Single-arm, Open-label, Multicenter Phase 3 Study of the Contraceptive Efficacy, Safety and Tolerability of the AG200-15 Transdermal Contraceptive Delivery System (TCDS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Feb 2022
Price :
$35
*
At a glance
- Drugs Ethinylestradiol/levonorgestrel (Primary)
- Indications Pregnancy
- Focus Registrational; Therapeutic Use
- Acronyms SECURE
- Sponsors Agile Therapeutics
- 30 Apr 2021 According to an Agile Therapeutics media release, post hoc analysis of this study will be presented at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting from April 30 - May 2.
- 30 Nov 2020 According to an Agile Therapeutics media release, results from this study have been published online in Contraception and will also appear in a future print edition of the journal.
- 28 Nov 2020 Results published in the Contraception